Last week, we had the opportunity to partner with Jesse Erasmus, Acting Assistant Professor of the University of Washington School of Medicine and Director of Virology at HDT Bio, presenting a webinar titled Development of a replicon RNA vaccine platform for response to emerging variants of SARS-CoV-2.
We talked through key attributes for an effective pandemic vaccine, the benefits of nucleic acids as rapid vaccines for pandemics, the process for developing a self-amplifying (replicon), repRNA (VEEV), and LION serving as a highly stable formulation for delivery of RNA vaccine development.
In short, this webinar covered RNA vaccine development fundamentals for every scientist working to address emerging SARS-CoV-2 variants to learn from. And to give you a glimpse, here are some key takeaways from the webinar.
- LION/repRNA-CoV2S provides long-lived protective immunity in a non-human primate model of infection
- LION is a highly stable formulation for delivery and long-term storage of RNA vaccines that is amenable to rapid scale-up
- Multivalent or heterologous prime/boost strategies may be necessary for long-lived broad protective immunity
- The BioXp™ system enabled Dr. Erasmus to go from sequence design to synthesizing gene fragments to injecting mice with target vaccine candidates in only eight days
This was a great webinar that offered a wealth of information for those behind developing vaccines and therapeutics for emerging pandemics. If you couldn’t attend, you can view the recording.